What is the clinical evidence from this study?

Study design: Other. Population: Arrhythmic substrate / Ventricular tachycardia. Intervention: Epac activator 8-CPT vs. Untreated hearts. Primary outcome: Ventricular tachycardia incidence (p=<.05).

March 19, 2017Clinical and Experimental Pharmacology and PhysiologyOpen Access

Arrhythmic effects of Epac‐mediated ryanodine receptor activation in Langendorff‐perfused murine hearts are associated with reduced conduction velocity

Q: What are the key findings of this study?

Acute RyR2 activation with the Epac activator 8-CPT reversibly induced ventricular tachycardia in specific association with reduced conduction velocity in murine hearts (P<.05).

View Full Paper

Ask AI

Bookmark

Key result

Acute RyR2 activation with the Epac activator 8-CPT reversibly induced ventricular tachycardia in specific association with reduced conduction velocity in murine hearts (P<.05).

Why the study?

Does Epac-mediated RyR2 activation induce ventricular tachycardia and reduce conduction velocity in murine hearts?

Population

Langendorff-perfused wild-type mouse ventricles

Comparison

Epac activator 8-CPT (8--2'-O-methyladenosine-3'… vs Untreated hearts

Design

Preclinical

Authors

MLMengye LiFirst Hospital of China Medical University SHSandeep S HothiNew Cross Hospital SSSamantha C. SalvageSt George's Hospital

Discussion

Member takes

Implication

Indicates Epac-RyR2 pathway in murine VT; hypothesis-generating for human arrhythmogenesis and targets.

Structured PICO

Does Epac-mediated RyR2 activation induce ventricular tachycardia and reduce conduction velocity in murine hearts?

Population

Langendorff-perfused wild-type mouse ventricles used to explore the effects of Epac-mediated RyR2 activation on arrhythmic substrate and conduction velocity.

Intervention

Epac activator 8-CPT (8-(4-chlorophenylthio)-2'-O-methyladenosine-3',5'-cyclic monophosphate) and/or RyR2 blocker dantrolene

Comparator

Untreated hearts

Outcome

Ventricular tachycardia (VT) incidence and action potential (AP) latenciessurrogate

Main Result

p-value: p=<.05

Acute RyR2 activation by Epac reversibly induces ventricular tachycardia associated with reduced conduction velocity in murine hearts.

Cite This Study

Li et al. (2017) studied Arrhythmic substrate / Ventricular tachycardia. Epac activator 8-CPT vs. Untreated hearts was evaluated on Ventricular tachycardia incidence (p=<.05). Acute RyR2 activation with the Epac activator 8-CPT reversibly induced ventricular tachycardia in specific association with reduced conduction velocity in murine hearts (P<.05).

synapsesocial.com/papers/6a6f035ec1a24a6142db4bdb https://doi.org/10.1111/1440-1681.12751

Topics

Ventricular arrhythmias

View Full Paper

Ask AI

Bookmark

Arrhythmic effects of Epac‐mediated ryanodine receptor activation in Langendorff‐perfused murine hearts are associated with reduced conduction velocity

Discussion

Member takes

Implication

Structured PICO

Main Result

Cite This Study

Topics

Arrhythmic effects of Epac‐mediated ryanodine receptor activation in Langendorff‐perfused murine hearts are associated with reduced conduction velocity

Discussion

Member takes

Implication

Structured PICO

Main Result

Cite This Study

Also Consider

Topics

Also Consider